<DOC>
	<DOCNO>NCT02824315</DOCNO>
	<brief_summary>The purpose study investigate steady-state pharmacokinetics ( PK ) simeprevir ( SMV ) , odalasvir ( ODV ) AL-335 ( metabolites ALS-022399 ALS 022227 ) , drug co-administered healthy Japanese participant .</brief_summary>
	<brief_title>Study Investigate Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir AL-335 Between 3 Direct Acting Antiviral Agents Simeprevir , Odalasvir AL-335 Steady State Healthy Japanese Participants</brief_title>
	<detailed_description />
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participant must Japanese participant reside outside Japan 5 year whose parent grandparents Japanese determine participant 's verbal report Participant must body mass index ( BMI : weight kilogram ( kg ) divide square height meter ) 18.0 30.0 kilogram per meter square ( kg/m^2 ) , extremes include , body weight less 50.0 kg Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening . If abnormality , participant may include Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document initial Investigator Participant must blood pressure ( participant supine 5 minute ) 90 140 milligram mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic . If blood pressure range , 2 repeat assessment permit Female participant must agree donate egg ( ovum , oocytes ) purpose assist reproduction study period 60 day last study drug administration last followup visit , whichever occur later Participant history liver renal insufficiency ( estimate creatinine clearance 80 milliliter per minute [ mL/min ] ) ; significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation Investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Participant past history heart arrhythmia ( example extra systolic beat tachycardia rest ) ; risk factor associate Torsade de Pointes hypokalemia family history short/long QT syndrome sudden unexplained death ( include sudden infant death syndrome ) first degree relative [ example sibling , offspring , biological parent ] ) Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant known allergy , hypersensitivity , intolerance simeprevir ( SMV ) , odalasvir ( ODV ) , AL335 excipients Participant woman pregnant , breastfeeding , plan become pregnant signing Informed Consent Form ( ICF ) 60 day last study drug administration last followup visit , whichever occur later</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>